Temporal Changes in Biomarkers, Functional Status, and Quality of Life Prior to Adverse Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction.
Saved in:
| Title: | Temporal Changes in Biomarkers, Functional Status, and Quality of Life Prior to Adverse Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. |
|---|---|
| Authors: | Lu H; Division of Cardiology, Lausanne University Hospital (CHUV), University of Lausanne (UNIL), Lausanne, Switzerland; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Claggett BL; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Vaduganathan M; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Desai AS; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Jhund PS; British Heart Foundation Glasgow Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, Scotland, United Kingdom., Voors AA; Department of Cardiology, University Medical Center of Groningen, University of Groningen, Groningen, the Netherlands., Senni M; University of Milano-Bicocca, Milan, Italy; Papa Giovanni XXIII Hospital, Bergamo, Italy., Zannad F; Université de Lorraine, Inserm Clinical Investigation Centre, CHU, Nancy, France., Pitt B; School of Medicine, University of Michigan, Ann Arbor, Michigan, USA., Shah SJ; Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA., Lam CSP; National Heart Centre Singapore and Duke-National University of Singapore, Singapore, Singapore., Scheerer MF; Bayer AG, Global Medical Affairs, Berlin, Germany., Scalise A; Cardiology and Nephrology Clinical Development, Bayer Hispania S.L., Barcelona, Spain., Mueller K; Bayer AG, Pharmaceuticals, R&D, Wuppertal, Germany., Berger M; Bayer AG, Pharmaceuticals, R&D, Wuppertal, Germany., Goea L; Bayer AG, Pharmaceuticals, R&D, Wuppertal, Germany., McMurray JJV; British Heart Foundation Glasgow Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, Scotland, United Kingdom., Solomon SD; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. Electronic address: ssolomon@bwh.harvard.edu. |
| Source: | JACC. Heart failure [JACC Heart Fail] 2025 Oct; Vol. 13 (10), pp. 102590. Date of Electronic Publication: 2025 Aug 25. |
| Publication Type: | Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 101598241 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2213-1787 (Electronic) Linking ISSN: 22131779 NLM ISO Abbreviation: JACC Heart Fail Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
